Omega-3’s New Gut Mechanism for Lowering Triglycerides

Fish oil may lower triglycerides partly by putting a brake on fat digestion in the gut—not only by changing what the liver sends into circulation. That is the intriguing conclusion of research summarized in a 2021 Journal of Clinical Investigation editorial. The catch matters: the direct mechanism comes from mouse experiments, with only an early signal that related compounds rise in human plasma.

The finding does not rewrite the practical case for omega-3 supplements, nor does it justify a new protocol. It does add a plausible second route by which DHA and EPA could reduce triglycerides: the liver may convert omega-3 fats into bile-borne compounds that reduce intestinal triglyceride breakdown and absorption.

A second route beyond the liver

The standard account of omega-3 triglyceride lowering centers on the liver. EPA and DHA can reduce the production and secretion of triglyceride-rich very-low-density lipoprotein (VLDL) particles, in part through effects on SREBP-1c and PPARα. Less VLDL leaving the liver means fewer triglycerides circulating in blood.

The newer work adds an intestinal mechanism. In the experiments discussed by the JCI editorial, omega-3 supplementation increased a class of lipid metabolites called N-acyl taurines, or NATs. The standout molecule was C22:6 NAT: DHA chemically joined to taurine. It accumulated in bile and plasma, then acted in the intestinal lumen to inhibit the lipases that hydrolyze dietary triglycerides. If lipases break down less fat, the intestine absorbs less of it.

That sequence offers a tidy biological explanation:

• The liver conjugates an omega-3 fatty acid with taurine.
• The resulting NAT enters bile and reaches the intestinal lumen.
• There, C22:6 NAT inhibits triglyceride hydrolysis.
• Reduced hydrolysis limits lipid absorption and lowers circulating triglycerides in mice.

The enzyme that makes these conjugates is bile acid:amino acid N-acyltransferase, or BAAT. BAAT is expressed in the liver, which makes it a logical target for drug discovery: amplify a beneficial NAT signal, perhaps without relying on large amounts of dietary omega-3. That is a research hypothesis, not a drug-development success story. The published commentary describes no BAAT drug candidate, human inhibitor study, or clinical trial.

What the mouse work found—and what it did not

According to the Bornfeldt et al. commentary, omega-3-derived NATs reduced triglyceride hydrolysis and lipid absorption in mouse models. Mice fed a high-fat diet also had lower plasma triglycerides and less hepatic triacylglycerol accumulation when this pathway was active. The editorial frames NAT production as an additional mechanism alongside reduced hepatic VLDL secretion, not a replacement for it.

That distinction prevents a common overreach. The study does not show that the gut pathway explains most omega-3 triglyceride lowering in people. It does not provide a human estimate of how much of the effect comes from reduced absorption versus reduced VLDL secretion. Nor does the available editorial report the key quantitative details a reader would want: NAT concentrations, fold changes, lipase inhibition values, mouse effect sizes, sample sizes, confidence intervals, or dose-response data.

BAAT is a compelling mechanistic node, but "druggable" means a target is biologically identifiable. It does not mean a treatment exists.

The biology may also translate imperfectly. Mice and humans differ in bile acid composition, intestinal transit, and enzyme activity. The editorial reports NAT accumulation in human plasma, which makes the hypothesis more than a mouse-only curiosity. But plasma detection cannot establish that a standard fish-oil dose creates enough NAT in the human gut lumen to inhibit dietary fat absorption. It also cannot prove that NATs caused any observed triglyceride change.

Human evidence supports omega-3 effects, not this mechanism

Human trial data support the broader claim that fish-oil omega-3s can change lipid markers. In a three-month randomized, double-blind, placebo-controlled study, Xia et al. assigned 110 people with type 2 diabetes to fish-oil capsules or corn-oil capsules, with 55 participants in each group. At three months, the fish-oil group had lower triglycerides than the corn-oil group (p = 0.034), along with lower total cholesterol (p < 0.001), LDL cholesterol (p = 0.048), non-HDL cholesterol (p = 0.046), fasting blood glucose (p = 0.039), glycated hemoglobin (p = 0.048), and HOMA-IR (p = 0.022).

Those are controlled human results, but they do not validate the NAT pathway. The trial measured gut microbiota, serum lipids, glycemic measures, and serum lipid metabolites; it did not measure NATs as intermediates. Its findings show that fish oil changed metabolic markers in this population over three months, not why it did so.

A 2025 Mendelian-randomization study by Fabian et al. adds a different kind of support. It used genetic instruments for oily-fish intake and fish-oil supplementation from UK Biobank data, involving 460,443 and 461,384 participants, respectively, to examine causal effects on epigenetic-age acceleration and related serum markers. This design can reduce some forms of confounding that plague ordinary diet studies. It still does not test supplementation in a clinical setting, measure NATs, or identify BAAT as the cause of a triglyceride effect.

Taurine makes the hypothesis more plausible, not proven

NATs join two molecules with metabolic relevance: an omega-3 fatty acid and taurine. That makes the conjugate scientifically interesting, especially because taurine itself has human trial evidence. A 2024 systematic review and meta-analysis of randomized trials found that taurine supplementation reduced metabolic-syndrome risk markers, including plasma triglycerides and blood pressure.

Still, supplemental taurine is not the same intervention as an endogenously made DHA-taurine conjugate. The studies in that review did not establish that NATs reproduce taurine's effects, that taurine explains C22:6 NAT activity, or that combining DHA with taurine creates a larger effect than either compound alone. The connection is biologically plausible, but indirect.

The liver-fat observation also deserves restraint. The NAT pathway protected high-fat-fed mice against hepatic triacylglycerol accumulation. Human dietary trials show that liver fat can respond to diet: a 2024 meta-analysis of randomized trials in nonalcoholic fatty liver disease compared Mediterranean and low-fat dietary patterns using outcomes that included intrahepatic lipid and liver enzymes. That broader context does not validate NATs as a treatment for fatty liver. It simply makes hepatic triglyceride accumulation a clinically relevant outcome worth studying in people.

A lower triglyceride number is not a cardiovascular verdict

Mechanistic excitement can outrun clinical evidence. Triglycerides are a useful metabolic marker, but lowering them does not automatically improve every cardiovascular outcome in every population. A 2024 Cochrane review of omega-3 fatty acids for intermittent claudication found no consistent clinically meaningful benefit for symptoms of peripheral artery disease. That review addresses a specific vascular condition, not the NAT mechanism and not triglyceride lowering itself. Its lesson is narrower: a favorable biomarker change does not tell us, by itself, which patient outcomes will improve.

There is also no contradictory evidence for the NAT mechanism in the published material reviewed here. That absence should not be mistaken for consensus. The decisive studies have not yet been done: controlled human pharmacokinetic work measuring NAT concentrations after omega-3 supplementation; evidence that NATs reach the intestinal lumen at active concentrations; and human tests showing that BAAT activity is necessary for triglyceride lowering. Secondary analyses that separate absorption effects from hepatic VLDL effects would help, too.

What to do with this now

Do not change your fish-oil dose because of BAAT or C22:6 NAT. Human evidence supports fish oil's ability to improve triglycerides in at least some controlled settings, while the intestinal NAT mechanism remains preclinical with a preliminary human plasma signal. The established hepatic explanation still carries the main weight.

Watch for human studies that measure NATs after defined omega-3 doses and connect those measurements to triglyceride absorption and blood triglycerides. Until then, BAAT is an elegant lead for metabolism research—not a reason to treat fish oil like a newly discovered fat-blocking drug.